Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

BLA761530

Drug and asset intelligence for BLA761530 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Viridian Therapeutics →

Mechanism of action

Monoclonal Antibody

Recent signals(1)

RegulatoryJuly 3, 2026

FDA Approves BLA761530 (LUMVOA) from Viridian Therapeutics

The FDA has approved BLA761530, known as LUMVOA, submitted by Viridian Therapeutics.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— BLA761530

Monitor market launch timelines and initial sales performance of LUMVOA.

July 3, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Monoclonal Antibody →
Oncology →
Oncology · Monoclonal Antibody →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.